Biodesix Inc

Biodesix, Inc. is a diagnostic solutions company that aims to transform patient care and improve outcomes through personalized diagnostics. The company generates revenue from two primary sources: Biodesix Lung Diagnostic Testing and Biodesix Development Services. Lung Diagnostic Testing provides blood-based diagnostic testing services for healthcare providers, utilizing five proprietary tests. Development Services offers diagnostic testing and consulting to biopharmaceutical, life sciences, and diagnostic companies. In 2025, Biodesix achieved an estimated total revenue of $88.5 million, marking a 24% increase over 2024. Lung Diagnostic Testing contributed $79.2 million in revenue, a 22% increase, from 62,600 tests delivered, which was a 15% increase. Development Services generated $9.3 million in biopharmaceutical services revenue, a 41% increase. The company also enrolled over 1,500 patients in the CLARIFY study, which will gather patient outcomes and clinical information on 4,000 patients who received Nodify Lung® Nodule Risk Assessment testing. Operational efficiencies improved, with the gross margin percentage increasing to 81% from 78% in 2024. The company limited the growth in full-year Operating Expense, excluding Direct costs and expenses, to 10% over 2024, including non-cash share-based compensation expenses, while achieving 24% revenue growth.